SCHEMBL574618

SCHEMBL574618

NOC(=O)c1ccccc1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.63
LMNA P02545 3/20 0.63
HPGD P15428 7/20 0.59
HSD17B10 Q99714 6/20 0.59
ALOX15 P16050 1/20 0.59
KDM4E B2RXH2 7/20 0.58
ALDH1A1 P00352 6/20 0.58
MAPT P10636 2/20 0.58
TDP1 Q9NUW8 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.54
CA1 P00915 2/20 0.54
CA9 Q16790 2/20 0.54
CA12 O43570 1/20 0.54
CA2 P00918 1/20 0.54
HMGB1 P09429 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA7 P43166 1/20 0.54
NAPRT Q6XQN6 1/20 0.54
CA14 Q9ULX7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28540211 0.98 TSHR (0.61) TSHRLMNAHPGDHSD17B10ALOX15
Water SCHEMBL19915275 0.98 TSHR (0.61) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL734992 0.98 TSHR (0.61) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL734993 0.98 TSHR (0.61) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL679492 0.85 TSHR (0.50) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL16598169 0.82 LMNA (0.63) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL10203414 0.81 LMNA (0.68) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL3908136 0.81 LMNA (0.68) TSHRLMNAHPGDHSD17B10ALOX15
SCHEMBL29525350 0.81 LMNA (0.68) TSHRLMNAHPGDHSD17B10ALOX15
Salicylic Acid SCHEMBL8206603 0.80 ALDH1A1 (0.58) TSHRLMNAHPGDHSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013420-B1 METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME RIGEL PHARMACEUTICALS INC (US) 2023-11-01 EP claimed
EP-4054524-A1 COMPOSITIONS OF CLOFAZIMINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS OF TREATMENT COMPRISING THEM MannKind Corporation (US) 2022-09-14 EP claimed
CN-111470796-B Cement grinding aid 辽宁天宝华瑞建材有限公司 2022-03-15 CN claimed
US-20210246187-A1 BTNL3/8 TARGETING CONSTRUCTS FOR DELIVERY OF PAYLOADS TO THE GASTROINTESTINAL SYSTEM KING'S COLLEGE LONDON (GB) 2021-08-12 US claimed
CN-111470796-A Cement grinding aid 辽宁天宝华瑞建材有限公司 2020-07-31 CN claimed
CN-109970137-A A method of the hyperbranched magnetic material rich in functional group removes heavy-metal composite pollution object 天津工业大学 2019-07-05 CN claimed
US-20190099342-A1 COOLING PRODUCT SYMRISE AG (DE) 2019-04-04 US claimed
US-20190083632-A1 PLANT STEROIDS AND USES THEREOF DAVIDSON LOPEZ LLC (US) 2019-03-21 US claimed
CN-109234414-A The PAS drug resistance diagnosis marker of mycobacterium tuberculosis and its application 周琳 2019-01-18 CN claimed
CN-109078186-A A kind of stomach floating composition and preparation method thereof 江苏恒瑞医药股份有限公司 2018-12-25 CN claimed
US-20140220020-A1 IL-1 BINDING PROTEINS ABBVIE, INC. (US) 2014-08-07 US claimed
EP-2172185-B1 Cosmetic material comprising octyl hydroxy stearate oligomer PARAHERMOSA CO LTD (JP) 2011-11-23 EP claimed
WO-2011056948-A2 METHODS OF TEXTURING SURFACES FOR CONTROLLED REFLECTION ADVANCED TECHNOLOGY MATERIALS, INC. (US) 2011-05-12 WO claimed
CN-101460060-A Compositions and methods for topical treatment of tar-responsive skin disorders TRISTRATA INC (US) 2009-06-17 CN claimed
EP-1581206-A4 TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES VELA ACQUISITION CORP (US) 2009-01-07 EP claimed
US-20080131439-A1 METHODS OF DIAGNOSING INFLAMMATORY BOWEL DISEASE PROMETHEUS LABORATORIES INC. (US) 2008-06-05 US claimed
EP-1581206-A1 TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES Vela Pharmaceuticals Inc. (US) 2005-10-05 EP claimed
EP-1568700-A1 S-triazine derivatives containing at least two silated p-aminobenzalmalonate groups, sunscreen compositions containing these derivatives as well as the use of the derivatives L'OREAL (FR) 2005-08-31 EP claimed
US-20040138209-A1 Treatment of inflammatory disorders with 2,3- benzodiazepines VELA PHARMACEUTICALS, INC. 2004-07-15 US claimed
WO-2004050080-A1 TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-06-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138209-A1 Treatment of inflammatory disorders with 2,3- benzodiazepines LTB4R2, LTB4R, GABRA4 TSHR 327/4885LMNA 1715/4885HPGD 689/4885
US-20190099342-A1 COOLING PRODUCT TRPA1, TRPV2, NISCH TSHR 2965/4885LMNA 2013/4885HPGD 201/4885
US-20190083632-A1 PLANT STEROIDS AND USES THEREOF CYP46A1, CYP17A1, NR1H4 TSHR 3116/4885LMNA 4395/4885HPGD 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.